Preliminary mid-stage data from two rival TROP2-targeting ADCs advanced by AstraZeneca/Daiichi Sankyo and Gilead, combined with immune checkpoint inhibitors, have provided a first glance at the risk-benefit balance of this approach in non-small cell lung cancer. And although Gilead noticed a slightly higher response rate, analysts called the results “broadly…
Click here to view original post
